Purpose. To determine whether intra-articular tranexamic acid (TXA) use after total knee arthroplasty (TKA) results in decreased postoperative blood transfusion and length of hospital stay. Methods. Medical records of 1981 patients (mean age, 69.2 years) who underwent primary TKA with (n=1006) or without (n=975) TXA use by any of 4 knee arthroplasty surgeons were reviewed. TXA (3000 mg/30ml) was administered via an epidural catheter into the knee joint after wound closure. Postoperative blood transfusion was given to patients with haemoglobin (Hb) level <80 g/dl on days 1 and 2 or with symptoms of acute anaemia. 2016;24(1):3-6 respect to the reduction in blood transfusion was AU$143.68 per patient. When the change in length of hospital stay and TXA costs were included, the overall saving was AU$631.36 per patient. Conclusion. Intra-articular TXA use can reduce costs as a result of decreased blood transfusion rate and length of hospital stay in patients undergoing TKA.
introduction
Total knee arthroplasty (TKA) may result in considerable blood loss necessitating blood transfusion, 1, 2 which may lead to disease transmission, haemolysis, anaphylaxis, and death, 3 as well as further treatment and increased overall healthcare costs. It is appropriate to decrease the financial burden on the health sector without compromising patient care. 4 Tranexamic acid (TXA) is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin.
It binds to specific sites on both plasminogen and plasmin, a molecule responsible for the degradation of fibrin. 5 The beneficial effects of TXA in TKA have been highlighted. [6] [7] [8] In a meta-analysis, intravenous, oral, and topical TXA use during TKA significantly reduced total blood loss and the proportion of patients who required blood transfusion.
9 It is also cost-effective. [10] [11] [12] [13] Hospitalisation cost savings of $900 to $1500 per patient have been reported. 10, 11 This study aimed to determine whether intraarticular TXA use after TKA results in decreased postoperative blood transfusion and length of hospital stay.
Materials and Methods
Ethics waiver was given by the ethics committee of our private teaching hospital. Medical records of 1981 patients (mean age, 69.2 years) who underwent primary TKA with (n=1006) or without (n=975) TXA use from 2009 to 2014 by any of 4 knee arthroplasty surgeons were reviewed. Patients who underwent unicompartmental, bilateral, or revision knee surgery were excluded. Each surgeon performed TKA without TXA use until a particular time period, after which TXA was used for all subsequent surgeries.
The TKA was performed through a medial parapatellar approach and under spinal anaesthesia combined with sedation (unless general anaesthesia was indicated), with all 4 surgeons using the same technique throughout the period. A tourniquet was applied only for the initial soft tissue exposure and was released soon after.
TXA (3000 mg/30ml) was administered via an 18-gauge epidural catheter into the knee joint after wound closure to prevent leakage. A sterile dressing and a compression dressing were applied. The catheter was removed on the next day after injecting local anaesthetic through it in patients with or without TXA use. TXA was not suctioned out but left in situ. No drain was used before or after administration of TXA.
Postoperative blood transfusion was given to patients with haemoglobin (Hb) level <80 g/dl on days 1 and 2 or with symptoms of acute anaemia. Thromboembolic prophylaxis included mechanical calf compression, thrombo-embolic deterrent stockings, early mobilisation, and the use of aspirin or low molecular weight heparin. Patients were allowed to mobilise within 24 hours of TKA. Discharge plan was standardised.
The cost of 1000 mg of TXA, the cost of one unit of packed red blood cells, and the cost per day spent in hospital were AU$41.62, AU$610, and AU$1000 respectively.
TKA patients with or without TXA use were compared using independent t-test for continuous variables. The proportion of patients transfused and the number of units transfused per 100 patients between the 2 groups was compared using the Fisher's exact test. A p value of <0.05 was considered statistically significant. the change in length of hospital stay and TXA costs were included, the overall saving was AU$631.36 per patient (Table) .
results

TKA
discussion
Blood loss after TKA increases the financial burden secondary to blood transfusions and the increased morbidity associated with knee joint swelling and wound complications. Intravenous or intra-articular TXA reduces postoperative blood loss, without an associated increase in deep vein thrombosis or pulmonary embolism in patients undergoing TKA. 14 TXA use decreases blood loss and necessitates fewer blood transfusions. 15 TXA reduces blood loss by 29% and reduces the risk of receiving a blood transfusion by 45%. 16 Intra-articular TXA reduces blood loss and knee joint swelling. 17 Intra-articular TXA is superior to intravenous TXA with respect to mean blood loss, requirement of blood transfusion, and drop in Hb, 18 as well as total blood loss, blood transfusion, and drain output. 19 Nonetheless, one study reported no difference between intravenous and intra-articular TXA in terms of fall in Hb and drain blood loss. 20 TXA use has been reported to reduce the length of hospital stay in TKA patients from 8.92 to 7.09 days, 21 with an average decrease of 1.2 days 22, 23 or 0.6 day, 10 which is similar to our results. Topical TXA in primary total knee and hip arthroplasty results in a saving of $83.73 per patient based on transfusion costs alone. 13 The financial benefit is £2.04 for a 70 kg patient with oral TXA use. 12 The total hospitalisation savings have been reported to be $1500 per patient after topical TXA use, 10 and $879 after TXA use.
11
There were several limitations to our study. The transfusion costs, either for blood or TXA, were assumed to be the same. The length of hospital stay and recovery may have been influenced by the additional use of pain medications through the intra-articular catheter. In addition, the recognised morbidities associated with increased bleeding in TKA such as increased pain, swelling, woundrelated complications, and reduced range of motion were not taken into account. The morbidities and complications associated with transfusions were not measured. Due to the lack of standardisation of reporting of complications, complications were not reported. After adjusting for all confounders, TXA use may save AU$31.36 only, which was achieved by reducing the number of transfusions alone. TXA does not increase the risk of deep vein thrombosis and should not affect costs.
conclusion
Intra-articular TXA use can reduce costs as a result of decreased blood transfusion rate and length of hospital stay in patients undergoing TKA.
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